AGIOS PHARMACEUTICALS, INC. Increase (Decrease) in Due from Related Parties, Current
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase (Decrease) in Due from Related Parties, Current of -$44.00 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent · last filed 2017-08-08
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for the quarter ending 2017-06-30 was -$6.42M, a 718.19% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for the quarter ending 2017-03-31 was $6.38M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for the quarter ending 2016-12-31 was -$3.30M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for the quarter ending 2016-09-30 was $329.00K.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for fiscal 2016 was -$3.34M, a 292.67% decline from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for fiscal 2015 was $1.73M, a 71.19% decline from fiscal 2014.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for fiscal 2014 was $6.02M, a 1163.87% increase from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in due from related parties, current for fiscal 2013 was $476.00K.
| Period end | Increase (Decrease) in Due from Related Parties, Current 3 month | Increase (Decrease) in Due from Related Parties, Current 6 month | Increase (Decrease) in Due from Related Parties, Current 9 month | Increase (Decrease) in Due from Related Parties, Current 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$6.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$44.00K 10-Q · filed 2017-08-08 | -$3.34M derived: sum of 3 quarters · filed 2017-08-08 | -$3.01M derived: sum of 4 quarters · filed 2017-08-08 |
| 2017-03-31 | $6.38M 10-Q · filed 2017-05-04 | $3.08M derived: sum of 2 quarters · filed 2017-05-04 | $3.41M derived: sum of 3 quarters · filed 2017-05-04 | $4.45M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$2.97M derived: sum of 2 quarters · filed 2017-02-16 | -$1.93M derived: sum of 3 quarters · filed 2017-08-08 | -$3.34M 10-K · filed 2017-02-16 |
| 2016-09-30 | $329.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.37M derived: sum of 2 quarters · filed 2017-08-08 | -$43.00K 10-Q · filed 2016-11-03 | -$895.00K derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$372.00K 10-Q · filed 2017-08-08 | -$1.22M derived: sum of 3 quarters · filed 2017-08-08 | -$2.62M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | -$1.41M 10-Q · filed 2017-05-04 | -$2.26M derived: sum of 2 quarters · filed 2017-05-04 | -$3.66M derived: sum of 3 quarters · filed 2017-05-04 | -$202.00K derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | -$852.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$2.25M derived: sum of 2 quarters · filed 2017-02-16 | $1.21M derived: sum of 3 quarters · filed 2017-02-16 | $1.73M 10-K · filed 2017-02-16 |
| 2015-09-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $2.06M derived: sum of 2 quarters · filed 2016-11-03 | $2.58M 10-Q · filed 2016-11-03 | -$9.68M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $3.98M 10-Q · filed 2016-08-08 | -$8.29M derived: sum of 3 quarters · filed 2017-02-16 | $10.47M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | $524.00K 10-Q · filed 2016-05-09 | -$11.74M derived: sum of 2 quarters · filed 2017-02-16 | $7.02M derived: sum of 3 quarters · filed 2017-02-16 | $4.40M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | -$12.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $6.49M derived: sum of 2 quarters · filed 2017-02-16 | $3.87M derived: sum of 3 quarters · filed 2017-02-16 | $6.02M 10-K · filed 2017-02-16 |
| 2014-09-30 | $18.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $16.14M derived: sum of 2 quarters · filed 2015-11-06 | $18.28M 10-Q · filed 2015-11-06 | |
| 2014-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$476.00K 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $2.14M 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | $476.00K 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |